Skip to main content
SpringerLink
Log in

Is there a Need for an Independent Centre for Pharmacoeconomics in the UK?

  • Leading Article
  • UK Centre for Pharmaeconomics
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Association of the British Pharmaceutical Industries (ABPI).Limiting medicines - reducing choice. ABPI Briefing. ABPI. London.November 1992

    Google Scholar 

  • Bateman DN. The selected list. British Medical Journal 306: 1141–1142,1993

    Article  PubMed  CAS  Google Scholar 

  • Bligh J, Walley T. The UK indicative prescribinging scheme. Pharmaco Economics 2: 137–152, 1992

    Article  CAS  Google Scholar 

  • Bradlow J, Coulter A. Effect of fundholding and indicative prescribing scheme on general practitioners’ prescribing costs. British Medical Journal 307: 1186–1189, 1993

    Article  PubMed  CAS  Google Scholar 

  • Charlton B, Management of science. Lancet 342: 99–100, 1993

    Article  PubMed  CAS  Google Scholar 

  • Davey P. Malek M. Dodd T. Pharmaro economics: the truth.Lancet 341;1097–1098,1993

    Article  PubMed  CAS  Google Scholar 

  • Denby A. Wells N, Interpreting economic evaluations of medicines: a new role for the pharmacist? Pharmaco Economics 2: 95–98, 1992

    Article  CAS  Google Scholar 

  • Department of Health. Improving prescribing. Sections 1.2 and 2.21,Her Majesty’s Stationery Office. London. 1990

    Google Scholar 

  • Department of Health. Working for patients. Her Majesty’s Stationery Office. London, 1993

    Google Scholar 

  • Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmaco Economics 3: 354–361, 1993

    Article  CAS  Google Scholar 

  • Drummond M. The role of economic evaluation in the pricing of modern pharmaceutical products: I-IV. pp. 7-8, 18-19,32-33, 38-42, Pharmaceutical Times. December 19811-March 1990

    Google Scholar 

  • Drummond M. Australian guidelines for cost effectiveness studies of pharmaceuticals - the thin end of the boomerang? Centre for Health Economics. University of York Discussion Paper no. 88,1991

    Google Scholar 

  • Drummond MF. Economic evaluation of pharmaceuticals: science or marketing? Pharmaco Economics 1: 8–13, 1992

    Article  CAS  Google Scholar 

  • Drummond M, Rutten M. Brenna A. Pinto CG, Horisberger B. et al. Economic evaluation of pharmaceuticals: a European perspective.Pharmaco Economics 4: 113–186, 1993

    Article  Google Scholar 

  • EditoriaL Economics for medical students, Lancet 2: 200. 1989

  • Editoria L Farewell to promoting good-buys? Lancet 338: 416–417, 1991

    Google Scholar 

  • Editorial. First UK ‘blacklist’ candidates notified. Scrip 28. May (1824):3,1993

    Google Scholar 

  • Editorial. UK DoH moves on economic analysis. Scrip, 12 March (1802):2,1993

    Google Scholar 

  • Editorial, UK DoH exploring cost benefit. Scrip. 25 May (1823): 2.1993

    Google Scholar 

  • EditoriaL Research and effective health care. Lancet 342: 64–65.1993

  • Glennester H. General Practice fundholding in the UK: is it working Pharmaco Economics 2: 10–13, 1992

    Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. Pharmaco Economics 1: 54–67, 1992

    Article  CAS  Google Scholar 

  • Herxheimer A. Randomised controlled trials, the Cochrane collaboration. Journal of the Royal College of Physicians of London 271: 180, 1993

    Google Scholar 

  • Hillman AL. Eisenberg JM, Pauly MV, Bloom BS. Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical Companies. New England Journal of Medicine 324; 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Horton R.Pharmacoeconomical with the truth. Lancet 341: 752, 1993

    Article  Google Scholar 

  • Horton R. Medicines Information Bill. Lancet 341: 1208–1209. 1993

    Article  Google Scholar 

  • Klein R. The role of health economics. British Medical Journal 299:275–276,1989

    Article  PubMed  CAS  Google Scholar 

  • Maxwell M, Heaney D. Howie J. Noble S. General practice fund. holding: observations on prescribing patterns and costs using the defined daily dose method. British Medical Journal 307: 1190–1194,1993

    Article  PubMed  CAS  Google Scholar 

  • Maynard A. Medicines in 1M twenty first century: who decides? An economist’s perspective. Presesnted at the British Pharmaceutical Conference. 12th September 1991

    Google Scholar 

  • McGuire A. A Centre for pharmacoenomics? Presented at Economic evaluation of medicines: current; issues and future needs. National Health and Lung Institute, London, 15-16 March. 1993 Office of Health Economics. Compendium of health statistics. OHE. London. 1992

    Google Scholar 

  • Reilly A, Taylor R. Webster J. General practitioners’ attitudes towards the limited list. Journal of the Royal College of General Practitioners 36: 151–152, 1986

    PubMed  CAS  Google Scholar 

  • Ryan M, Yule B. Bond C. Taylor RJ. Scottish general practitioners’ attitudes and knowledge in respect of prescribing. British Medical Journal 300: 1316–1318. 1990

    Article  PubMed  CAS  Google Scholar 

  • Smith R. Where is the wisdom? The poverty of medical evidence. British Medical Journal 303: 798–799. 1991

    Article  PubMed  CAS  Google Scholar 

  • Walley T, Edwards RT. Health economics in primary care in the UK: containment of drug costs. Pharmaco Economics 3: 100–106, 1993

    Article  CAS  Google Scholar 

  • Well. N. Regulation of The pharmaceutical industry; and now pharmaeconomic research? Pharma Economics 2: 435–439, 1992

    Article  Google Scholar 

  • Zammit-Lucia J. The use of extemal enpertise: the issues surrounding commisioned research. Presented at Economic evaluation of medicines: current issues and future needs. National Heart and Lung Institute, London, 15-16 March, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, University of Liverpool, PO Box 141, Liverpool, L69 3BX, England

    Tom Walley

  2. Department of Public Health, University of Liverpool, Liverpool, England

    Rhiannon T. Edwards

Authors
  1. Tom Walley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rhiannon T. Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walley, T., Edwards, R.T. Is there a Need for an Independent Centre for Pharmacoeconomics in the UK?. Pharmacoeconomics 5, 93–100 (1994). https://doi.org/10.2165/00019053-199405020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199405020-00003

Keywords

Search

Navigation